MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
ARTIVION, INC. (AORT)
ARTIVION, INC. (AORT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
$21,552K
Free Cash flow
-$12,014K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of long-t...
Non-cash compensation
Change in fair value of continge...
Others
Negative Cash Flow Breakdown
Acquisition of endospan, net of ...
Net (loss) income
Capital expenditures
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-13,510
1,417
2,426
6,502
Depreciation and amortization
6,748
6,340
5,757
5,717
Non-cash compensation
8,164
8,414
4,083
6,135
Non-cash lease expense
1,315
1,297
1,346
1,314
Write-down of inventories and deferred preservation costs
1,306
1,062
1,121
1,400
Non-cash interest expense
-
-
1,705
-
Deferred income taxes
-897
-524
1,521
-1,253
Change in fair value of contingent consideration
7,970
1,740
5,310
2,600
Endospan fair value adjustments
-
-
-2,337
-
Losses on inducement/extinguishment of debt
0
-
0
0
Gain from sale of non-financial assets
-
-
3,500
3,500
Other
-3,127
537
-94
108
Receivables
5,211
2,760
6,345
-8,736
Inventories and deferred preservation costs
4,373
6,379
3,714
6,042
Prepaid expenses and other assets
3,985
1,286
-2,905
-1,512
Accounts payable, accrued expenses, and other liabilities
4,334
-8,704
9,376
-967
Net cash flows used in operating activities
-1,266
1,154
19,560
22,262
Capital expenditures
10,748
8,003
27,507
4,609
Acquisition of endospan, net of cash acquired
116,661
-
-
-
Payments under endospan agreements
-
-
8,000
0
Payments related to sale of non-financial assets
0
1,500
-
-
Proceeds from sale of non-financial assets, net
-
-
5,000
-
Payments for endospan agreements
-
1,000
-
-
Other
3,000
-
-
-
Net cash flows used in investing activities
-129,409
-10,503
-30,507
-4,609
Proceeds from issuance of long-term debt, net
148,875
-
0
0
Proceeds from revolving credit facility
-
-
0
0
Repayment of debt
0
0
3
73
Proceeds from exercise of stock options and issuance of common stock
1,375
1,250
3,461
5,154
Payment of debt issuance costs
-
-
0
1,750
Proceeds from financing insurance premiums
3,217
-
0
0
Principal payments on short-term notes payable
863
577
855
841
Redemption and repurchase of stock to cover tax withholdings
-
-
0
-
Other
-216
-210
-173
-173
Net cash flows provided by financing activities
152,388
463
2,430
2,317
Effect of exchange rate changes on cash and cash equivalents
-161
-258
-1
-20
Increase in cash and cash equivalents
21,552
-9,144
-8,518
19,950
Cash and cash equivalents beginning of period
55,764
64,908
73,426
53,463
Cash and cash equivalents end of period
77,316
55,764
64,908
73,426
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
AORT Cash Flow Sankey Diagram
Sankey diagram visualizing AORT cash flow for the period
Proceeds from issuance of
long-term debt, net
$148,875K
Proceeds from financing
insurance premiums
$3,217K
(3.21%↑ Y/Y)
Proceeds from exercise of
stock options and...
$1,375K
(-69.16%↓ Y/Y)
Net cash flows
provided by financing...
$152,388K
(2231.87%↑ Y/Y)
Canceled cashflow
$1,079K
Increase in cash and cash
equivalents
$21,552K
(165684.62%↑ Y/Y)
Canceled cashflow
$130,836K
Principal payments on
short-term notes payable
$863K
(55.78%↑ Y/Y)
Other
-$216K
(38.81%↑ Y/Y)
Non-cash compensation
$8,164K
(-42.37%↓ Y/Y)
Change in fair value of
contingent consideration
$7,970K
(3895.24%↑ Y/Y)
Depreciation and
amortization
$6,748K
(-38.57%↓ Y/Y)
Accounts payable,
accrued expenses, and...
$4,334K
(169.61%↑ Y/Y)
Non-cash lease expense
$1,315K
(-47.61%↓ Y/Y)
Write-down of inventories
and deferred...
$1,306K
(-45.10%↓ Y/Y)
Net cash flows used
in investing...
-$129,409K
(-1768.72%↓ Y/Y)
Net cash flows used
in operating...
-$1,266K
(34.81%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$161K
(-106.87%↓ Y/Y)
Canceled cashflow
$29,837K
Acquisition of endospan, net
of cash acquired
$116,661K
Capital expenditures
$10,748K
(55.21%↑ Y/Y)
Other
$3,000K
(949.86%↑ Y/Y)
Net (loss) income
-$13,510K
(-1708.33%↓ Y/Y)
Receivables
$5,211K
(-46.06%↓ Y/Y)
Inventories and deferred
preservation costs
$4,373K
(-20.79%↓ Y/Y)
Prepaid expenses and
other assets
$3,985K
(-35.88%↓ Y/Y)
Other
-$3,127K
(57.87%↑ Y/Y)
Deferred income taxes
-$897K
(-288.31%↓ Y/Y)
Buy us a coffee